Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-06-15

FDA Approved: EXEMESTANE — Supplemental Application (Cipla USA Inc.)

View source ↗

Summary

The FDA approved a supplemental application for exemestane (Cipla USA Inc.). This action approves a supplemental change to the product's labeling or use.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Exemestane (Exemestane)

Snippet

SUPPL AP for EXEMESTANE (EXEMESTANE)